RheumaFinder
ActiveSummary
The annual accounts of RheumaFinder for fiscal year 2025 show a net loss of 52% of the equity at the start of that year. The 2025 annual accounts show equity of €364k and a net result of €-284k. Its solvency ranks better than 33% of 17043 sector peers (fiscal year 2025). The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.6% (low).
Checked score
Credit advice for your own amount and term
Signals
Checked, nothing found (2)
Financials · fiscal year 2025, micro schema
Filed annual accounts As filed with the NBB · 2025 against 2024 · 43 lines
The notes to these accounts (17 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Directors · office · real estate
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Vlasgaardstraat 529000 Gent1 establishment unit
1 parcel
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44816K0663/00F002 | Flanders | 2,156 m² | 1 · 95 m² | 11.8 m · 4 fl. |
Linked by address, not proof of ownership
Public money · subsidies and aid
Flemish government
2023 to 2025 · 8 entries · 502,698 EUR awarded · 375,200 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2025 | 4 | 38,700 EUR | 183,700 EUR |
| 2024 | 3 | 10,500 EUR | 191,500 EUR |
| 2023 | 1 | 453,498 EUR | 0 EUR |
Similar companies · same sector, comparable size
Company data · Crossroads Bank
Scores and ratios are computed by Checked and are not a credit decision.